Literature DB >> 29460058

The Immunologic Paradoxes of IgG4-Related Disease.

Xiao Xiao1,2,3,4, Min Lian1,2,3,4, Weici Zhang5, M Eric Gershwin6, Xiong Ma7,8,9,10.   

Abstract

IgG4-related disease (IgG4-RD), which usually occurs in middle-aged and elderly men, is a newly recognized fibroinflammatory condition characterized by swelling and sclerosis of involved organs, increased IgG4-positive plasma cell infiltration in lesions, and elevated IgG4 concentration in serum. Despite growing interest in the research, the pathophysiological mechanism remains elusive. Most IgG4-RD patients respond well to steroid therapy initially, but recurrent and refractory cases are common, especially in advanced fibrotic stage. Recent studies have documented the heterogeneity of the B cell lineages, which suggests their multiple functions in IgG4-RD beyond IgG4 production, such as cytokine secretion, antigen presentation, autoantibody production, and modulation of T and B cell interactions. Thus, a critical balance exists between pathogenic and regulatory B subsets to prevent immunopathology. A prompt response to B cell depletion therapy reported in recent cases strongly suggests the imbalance within B cell lineages in IgG4-RD. A more precise understanding of the pathogenesis of IgG4-RD will open up new perspectives for therapeutic strategy. With a particular emphasis on the novel B cell-targeted therapeutic strategies, this review highlights the immunologic features of IgG4-RD and the possible roles of B cell lineages in the pathogenesis of IgG4-RD.

Entities:  

Keywords:  B cells; IgG4; IgG4-related disease; Plasmablasts; Rituximab

Mesh:

Substances:

Year:  2018        PMID: 29460058     DOI: 10.1007/s12016-018-8679-y

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  80 in total

1.  Rheumatoid arthritis: Defective IL-10-producing Breg cells.

Authors:  Dario Ummarino
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 2.  Belimumab for systemic lupus erythematosus.

Authors:  Bevra Hannahs Hahn
Journal:  N Engl J Med       Date:  2013-04-18       Impact factor: 91.245

3.  Clinical significance of B cell-activating factor in autoimmune pancreatitis.

Authors:  Hirofumi Yamanishi; Teru Kumagi; Tomoyuki Yokota; Nobuaki Azemoto; Mitsuhito Koizumi; Yuichi Kobayashi; Masanori Abe; Hidehiro Murakami; Yoichi Hiasa; Bunzo Matsuura; Hirofumi Kawamoto; Kazuhide Yamamoto; Morikazu Onji
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

4.  B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination.

Authors:  Takechiyo Yamada; Ke Zhang; Akiko Yamada; Daocheng Zhu; Andrew Saxon
Journal:  Am J Respir Cell Mol Biol       Date:  2005-01-24       Impact factor: 6.914

5.  Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process.

Authors:  J-Matthias Löhr; Ralf Faissner; Dirk Koczan; Peter Bewerunge; Claudio Bassi; Benedikt Brors; Roland Eils; Luca Frulloni; Anette Funk; Walter Halangk; Ralf Jesenofsky; Ralf Jesnowski; Lars Kaderali; Jörg Kleeff; Burkhard Krüger; Markus M Lerch; Ralf Lösel; Mauro Magnani; Michael Neumaier; Stephanie Nittka; Miklós Sahin-Tóth; Julian Sänger; Sonja Serafini; Martina Schnölzer; Hermann-Josef Thierse; Silke Wandschneider; Giuseppe Zamboni; Günter Klöppel
Journal:  Am J Gastroenterol       Date:  2010-04-20       Impact factor: 10.864

Review 6.  The role of B lymphocytes in the progression from autoimmunity to autoimmune disease.

Authors:  Gabriela Franco Salinas; Faouzi Braza; Sophie Brouard; Paul-Peter Tak; Dominique Baeten
Journal:  Clin Immunol       Date:  2012-10-22       Impact factor: 3.969

7.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

8.  Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis.

Authors:  Mark Topazian; Thomas E Witzig; Thomas C Smyrk; Jose S Pulido; Michael J Levy; Patrick S Kamath; Suresh T Chari
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382

9.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

10.  Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease.

Authors:  Wei Lin; Panpan Zhang; Hua Chen; Yu Chen; Hongxian Yang; Wenjie Zheng; Xuan Zhang; Fengxiao Zhang; Wen Zhang; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2017-02-10       Impact factor: 5.156

View more
  2 in total

1.  Highlighting the importance of early diagnosis in progressive multi-organ involvement of IgG4-related disease: A case report and review of literature.

Authors:  Jing Xue; Xue-Mei Wang; Yan Li; Li Zhu; Xiao-Ming Liu; Juan Chen; Shu-Hong Chi
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

Review 2.  The Cellular and Molecular Bases of Allergy, Inflammation and Tissue Fibrosis in Patients with IgG4-related Disease.

Authors:  Song-Chou Hsieh; Chieh-Yu Shen; Hsien-Tzung Liao; Ming-Han Chen; Cheng-Han Wu; Ko-Jen Li; Cheng-Shiun Lu; Yu-Min Kuo; Hung-Cheng Tsai; Chang-Youh Tsai; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.